Ursodeoxycholic Acid Ameliorates Apoptotic Cascade in the Rotenone Model of Parkinson’s Disease: Modulation of Mitochondrial Perturbations
- 788 Downloads
The recent emergence of ursodeoxycholic acid (UDCA) as a contender in modifying neurotoxicity in human dopaminergic cells as well as its recognized anti-apoptotic and anti-inflammatory potentials in various hepatic pathologies raised impetus in investigating its anti-parkinsonian effect in rat rotenone model. UDCA prominently improved motor performance in the open field test and halted the decline in the striatal dopamine content. Meanwhile, it improved mitochondrial function as verified by elevation of ATP associated with preservation of mitochondrial integrity as portrayed in the electron microscope examination. In addition, through its anti-inflammatory potential, UDCA reduced the rotenone-induced nuclear factor-κB expression and tumor necrosis factor alpha level. Furthermore, UDCA amended alterations in Bax and Bcl-2 and reduced the activities of caspase-8, caspase-9, and caspase-3, indicating that it suppressed rotenone-induced apoptosis via modulating both intrinsic and extrinsic pathways. In conclusion, UDCA can be introduced as a novel approach for the management of Parkinson’s disease via anti-apoptotic and anti-inflammatory mechanisms. These effects are probably linked to dopamine synthesis and mitochondrial regulation.
Key wordsUrsodeoxycholic acid Rotenone Caspases Dopamine Nuclear factor-κB ATP
The authors are grateful to Dr. Manal I. Salman, professor of Pathology, Faculty of Medicine, Ain Shams University, and vice director of Electron Microscopy Unit at Ain Shams University Specialized Hospital, for her efforts in the electron microscopic examinations.
Conflict of Interest
The authors declare that there are no conflicts of interest to disclose.
- 29.Martinez-Moya P, Romero-Calvo I, Requena P, Hernandez-Chirlaque C, Aranda CJ, Gonzalez R, Zarzuelo A, Suarez MD, Martinez-Augustin O, Marin JJ, de Medina FS (2013) Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis. Int Immunopharmacol 15(2):372–380CrossRefPubMedGoogle Scholar
- 32.Hayat M (1986) Basic techniques for transmission electron microscopy, 1st edn. Academic Press, OrlandoGoogle Scholar
- 47.Ishizaki K, Iwaki T, Kinoshita S, Koyama M, Fukunari A, Tanaka H, Tsurufuji M, Sakata K, Maeda Y, Imada T, Chiba K (2008) Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production. Eur J Pharmacol 578(1):57–64CrossRefPubMedGoogle Scholar
- 49.Rastogi RP, Sinha RP (2009) Apoptosis: molecular mechanisms and pathogenicity. EXCLI J 8:155–181Google Scholar
- 57.Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G (1993) Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 178(6):2207–2211CrossRefPubMedGoogle Scholar
- 65.Castro RE, Sola S, Ramalho RM, Steer CJ, Rodrigues CM (2004) The bile acid tauroursodeoxycholic acid modulates phosphorylation and translocation of bad via phosphatidylinositol 3-kinase in glutamate-induced apoptosis of rat cortical neurons. J Pharmacol Exp Ther 311(2):845–852CrossRefPubMedGoogle Scholar